TALPHERA INC
TLPHNASDAQTrading Snapshot
- Day Range
- $1.16 – $1.18
- 52-Week Range
- $0.69 – $1.57
- Volume
- $2.05B
- Avg Volume
- $2.12B
- Shares Outstanding
- 51.9M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $28,000
- Last Q Revenue
- $6,915
- P/E Ratio
- -3.7
- P/S Ratio
- 61760.5x
- EPS (TTM)
- $-0.20
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +61.6%
Why Investors Own TLPH
- ✓High-growth profile — revenue up +49.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TALPHERA INC
TLPH
StockOtter · stockotter.spaceAbout TALPHERA INC
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Talphera (TLPH) Upgraded to Buy: Here's What You Should Know
Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medical
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Upd
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medicall